Biomerica Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Biomerica is gedaald met een gemiddeld jaarlijks percentage van -14.1%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 13.1%. De inkomsten zijn groeide met een gemiddeld percentage van 2.9% per jaar.

Belangrijke informatie

-14.1%

Groei van de winst

-4.4%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	2.9%
Rendement op eigen vermogen	-115.3%
Nettomarge	-111.9%
Laatste winstupdate	31 Aug 2024

Recente prestatie-updates uit het verleden

Recent updates

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Jul 14

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Dec 03

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

Dec 02

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Sep 15

Biomerica (BMRA) Investor Presentation - Slideshow

Jun 14

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Jun 13

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Apr 04

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

Mar 08

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Feb 10

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Jan 15

Biomerica soars as its COVID-19 antigen test wins European nod

Jan 12

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

Dec 20

Biomerica clinical trial for IBS nears enrollment completion

Dec 09

How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?

Nov 23

Opbrengsten en kosten

Hoe Biomerica geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:BMRA Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Aug 24	6	-6	6	1
31 May 24	5	-6	5	1
29 Feb 24	5	-6	5	2
30 Nov 23	6	-6	5	2
31 Aug 23	5	-6	6	2
31 May 23	5	-7	6	2
28 Feb 23	10	-7	6	2
30 Nov 22	16	-6	6	2
31 Aug 22	19	-5	6	2
31 May 22	19	-5	6	2
28 Feb 22	15	-4	5	2
30 Nov 21	11	-7	5	2
31 Aug 21	7	-7	5	2
31 May 21	7	-7	6	2
28 Feb 21	9	-6	5	3
30 Nov 20	6	-5	4	2
31 Aug 20	7	-4	3	2
31 May 20	7	-2	2	2
29 Feb 20	5	-3	2	2
30 Nov 19	5	-2	2	2
31 Aug 19	5	-2	2	2
31 May 19	5	-2	2	2
28 Feb 19	5	-2	2	2
30 Nov 18	5	-2	2	2
31 Aug 18	5	-2	2	2
31 May 18	6	-1	2	1
28 Feb 18	6	-1	2	1
30 Nov 17	6	-1	2	1
31 Aug 17	6	-1	2	1
31 May 17	6	-1	2	1
28 Feb 17	6	-2	2	1
30 Nov 16	6	-2	2	1
31 Aug 16	5	-1	2	1
31 May 16	5	-1	2	1
29 Feb 16	5	0	2	1
30 Nov 15	5	0	1	1
31 Aug 15	5	0	1	1
31 May 15	5	0	1	1
28 Feb 15	5	0	2	1
30 Nov 14	5	0	2	0
31 Aug 14	5	0	2	0
31 May 14	5	0	2	0
28 Feb 14	5	0	1	0
30 Nov 13	5	0	1	0

Kwaliteitswinsten: BMRA is momenteel verliesgevend.

Groeiende winstmarge: BMRA is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: BMRA is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 14.1% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van BMRA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: BMRA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 12.2% ).

Rendement op eigen vermogen

Hoge ROE: BMRA heeft een negatief Return on Equity ( -115.26% ), omdat het momenteel verliesgevend is.

Biomerica Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2025 earnings released: US$0.078 loss per share (vs US$0.067 loss in 1Q 2024)

Full year 2024 earnings released: US$0.35 loss per share (vs US$0.50 loss in FY 2023)

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.12 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.16 loss in 1Q 2023)

Full year 2023 earnings released: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

Recent updates

Biomerica, Inc. Announces Direct-To-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain

First quarter 2025 earnings released: US$0.078 loss per share (vs US$0.067 loss in 1Q 2024)

Biomerica, Inc., Annual General Meeting, Dec 13, 2024

New major risk - Financial position

Full year 2024 earnings released: US$0.35 loss per share (vs US$0.50 loss in FY 2023)

Biomerica, Inc. Launches At-Home Sample Collection for inFoods IBS, Significantly Expanding Access for Millions of IBS Sufferers

Biomerica, Inc. Announces Infoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024

Biomerica, Inc. has filed a Follow-on Equity Offering in the amount of $5.5 million.

Biomerica Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2023)

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.12 loss in 2Q 2023)

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.16 loss in 1Q 2023)

Biomerica, Inc., Annual General Meeting, Dec 07, 2023

Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

Jack Kenny Joins Biomerica’S Board of Directors

Full year 2023 earnings released: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.008 loss in 3Q 2022)

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.089 loss in 2Q 2022)

Biomerica Appoints Brian E. Lacy, to the Company’s Scientific Advisory Board

Steve Sloan to Step Down as Chief Financial Officer of Biomerica, Inc

Biomerica, Inc. Announces Board Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1Q 2022)

Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test

Biomerica, Inc., Annual General Meeting, Dec 07, 2022

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

Biomerica, Inc. Appoints Robert Carlson as Chief Commercial Officer

Full year 2022 earnings released: US$0.36 loss per share (vs US$0.62 loss in FY 2021)

Biomerica reports FY results

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2021)

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Biomerica, Inc. Expects Completion of Patient Enrollment for Its Infoods Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial This Week

Price target increased to US$13.00

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.23 loss in FY 2020)

Biomerica Announces Notice of Allowance for Patent on Product Used to Diagnose and Treat Depression

Biomerica, Inc. Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment

Biomerica (BMRA) Investor Presentation - Slideshow

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.088 loss in 3Q 2020)

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

New 90-day high: US$8.00

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

New 90-day high: US$7.50

Second quarter 2021 earnings released: US$0.13 loss per share

Earnings beat expectations, revenue disappoints

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Biomerica, Inc. Receives CE Mark for its New Covid-19 Rapid Antigen Test for Detection of Covid-19 Infection

Analysts lower revenue estimates to US$8.51m

Biomerica soars as its COVID-19 antigen test wins European nod

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

New 90-day low: US$5.38

Biomerica, Inc. Announces Corporate Secretary Changes

Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment

Biomerica clinical trial for IBS nears enrollment completion